Novavax Stock News and Forecast: NVAX stock rises on vote for FDA approval


  • Novavax stock rises on Tuesday as FDA panel votes to recommend approval of its covid vaccine.
  • NVAX stock closes 6% higher Tuesday at $47.54.
  • NVAX soars another 20% afterhours on Tuesday.

Novavax (NVAX) stock rose sharply on Tuesday after the market closed when an FDA panel voted to recommend its covid vaccine. The shares had already been strong and rose 20% higher following the announcement. At the time of writing on Wednesday morning though, NVAX has given back about half of those gains to trade currently at $52.30, still 10% higher than Tuesday's regular session close.

Also read: Apple Stock Deep Dive: AAPL price target at $100 on falling 2023 revenues

Novavax stock news

The FDA Vaccines & Related Biological Products Advisory Committee (VRBPAC) voted 21 to 0 in favor of granting Emergency Use Authorization (EUA) to Novavax's covid vaccine. There was one abstention from the vote. The vote was based on data from a clinical trial involving 30,000 participants that showed 90.4% efficiency against covid. The vaccine has already been approved by numerous countries as well as already given Emergency Use Listing from the World Health Organization. This latest vote does not yet constitute approval. The FDA will have to rubber-stamp the VRBPAC recommendation. 

"The advisory committee's positive recommendation acknowledges the strength of our data and the importance of a protein-based COVID-19 vaccine developed using an innovative approach to traditional vaccine technology," said Stanley C. Erck, President and CEO. "In today's VRBPAC meeting, we heard the overwhelming support for our vaccine from physicians, healthcare organizations, and consumers who are eagerly anticipating a protein-based vaccine option."

Novavax stock forecast

Despite this apparent positive development NVAX stock remains in a powerful downtrend, so it remains to be seen if this is enough to reverse the decline. We may already be at the late stage of covid given its mutation and strong immunity in the developed world at least. We have witnessed a similar decline for Moderna (MRNA).

Moderna chart, daily

Novavax has shown a similar trait, and it has not been as productive as Moderna in vaccine distribution. NVAX had a classic double-top back in November and December, which led to the current decline. NVAX then declined to its long-term fair value zone, highlighted back in 2018 and 2019. The current retracement does look like an attractive entry point from a longer-term perspective. The first target is the small area of consolidation around $80. From there, a break higher to test the double bottom at $121 would seem likely.

NVAX chart, weekly


Like this article? Help us with some feedback by answering this survey:

Share: Feed news

Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.

If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.

FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.

The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.

Recommended content


Recommended content

Editors’ Picks

AUD/USD: The hunt for the 0.7000 hurdle

AUD/USD: The hunt for the 0.7000 hurdle

AUD/USD quickly left behind Wednesday’s strong pullback and rose markedly past the 0.6900 barrier on Thursday, boosted by news of fresh stimulus in China as well as renewed weakness in the US Dollar.

AUD/USD News
EUR/USD refocuses its attention to 1.1200 and above

EUR/USD refocuses its attention to 1.1200 and above

Rising appetite for the risk-associated assets, the offered stance in the Greenback and Chinese stimulus all contributed to the resurgence of the upside momentum in EUR/USD, which managed to retest the 1.1190 zone on Thursday.

EUR/USD News
Gold holding at higher ground at around $2,670

Gold holding at higher ground at around $2,670

Gold breaks to new high of $2,673 on Thursday. Falling interest rates globally, intensifying geopolitical conflicts and heightened Fed easing bets are the main factors. 

Gold News
Bitcoin displays bullish signals amid supportive macroeconomic developments and growing institutional demand

Bitcoin displays bullish signals amid supportive macroeconomic developments and growing institutional demand

Bitcoin (BTC) trades slightly up, around $64,000 on Thursday, following a rejection from the upper consolidation level of $64,700 the previous day. BTC’s price has been consolidating between $62,000 and $64,700 for the past week.

Read more
RBA widely expected to keep key interest rate unchanged amid persisting price pressures

RBA widely expected to keep key interest rate unchanged amid persisting price pressures

The Reserve Bank of Australia is likely to continue bucking the trend adopted by major central banks of the dovish policy pivot, opting to maintain the policy for the seventh consecutive meeting on Tuesday.

Read more
Five best Forex brokers in 2024

Five best Forex brokers in 2024

VERIFIED Choosing the best Forex broker in 2024 requires careful consideration of certain essential factors. With the wide array of options available, it is crucial to find a broker that aligns with your trading style, experience level, and financial goals. 

Read More

Forex MAJORS

Cryptocurrencies

Signatures